Comparative Pharmacology
Head-to-head clinical analysis: OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE versus OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE versus OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE.
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE vs OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx across vascular smooth muscle and cardiac muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Oral, one tablet once daily. Initial dose: olmesartan 20 mg/amlodipine 5 mg/hydrochlorothiazide 12.5 mg. Titrate based on response, max dose: olmesartan 40 mg/amlodipine 10 mg/hydrochlorothiazide 25 mg daily.
Oral, one tablet once daily. Starting dose: Olmesartan medoxomil 20 mg / hydrochlorothiazide 12.5 mg. Titrate up to maximum 40 mg / 25 mg daily as needed.
None Documented
None Documented
Olmesartan: terminal half-life 10-15 hours; supports once-daily dosing. Amlodipine: terminal half-life 30-50 hours; allows once-daily dosing with steady state reached after 7-8 days. Hydrochlorothiazide: terminal half-life 6-15 hours; prolonged in renal impairment.
Olmesartan: terminal half-life ~10–15 hours; no accumulation. Hydrochlorothiazide: terminal half-life ~6–15 hours; prolonged in renal impairment.
Olmesartan: ~40% excreted in urine (10-20% unchanged, rest as metabolites), ~60% in feces via bile. Amlodipine: ~60% excreted in urine (10% unchanged), 20-25% in feces. Hydrochlorothiazide: >95% excreted unchanged in urine.
Olmesartan: ~60% renal, ~35% fecal. Hydrochlorothiazide: ~70% renal (unchanged), ~30% biliary/fecal.
Category D/X
Category D/X
ARB
ARB